Who we are
The Centre has individual members – academics and fellows – who contribute through joint teaching, research and engagement activities to the Centre’s mission to make better healthcare accessible and affordable for all. Membership of Cambridge Centre Health Leadership & Enterprise CCHLE is open to all Cambridge Judge Business School faculty and doctoral students, who either contribute to an existing initiative or wish to establish a new initiative in accordance with our mission.
What we do
We develop themed initiatives that build coherent programmes of educational and research activities to support our mission. Led by passionate faculty members, our initiatives are developed carefully to generate or inspire breakthroughs in the field.
Drawing on business school faculty across management disciplines and a wide network of practice fellows and industry collaborators, we develop and publish research that addresses specific challenges of technological and business model innovation, as well as organisational, management and leadership challenges in the healthcare industry.
Developing leadership programmes, MBA masterclasses for healthcare leaders, MBA concentration and generating NHS engagement. Cambridge University Hospitals and CU Medical School have partnered with us for this initiative.
We work closely with leaders of the local and regional health system in a research, advisory and leadership development capacity to support the local and regional implementation of national NHS priorities on COVID , integrated care and population health.
Alongside our partner, Apollo Therapeutics, we are developing the biopharmaceutical MBA elective, generating research, Executive Education and engagement with the Cambridge biotech ecosystem.
Our faculty have produced an important book on this sector: From Breakthrough to Blockbuster: The Business of Biotechnology (2022), by DL Drakeman, LN Drakeman and N Oraiopoulos (named a Financial Times Business Top Title).
A joint initiative with our US partner SSM Health to develop and promote a novel not-for-profit business genre, called a healthcare utility, that enables collaboration between healthcare organisations with a goal to disrupt their supply chain and radically reduce costs, increasing access to essential healthcare products and services for all.
Faculty member and co-director Professor Feryal Erhun will oversee this initiative – her area of expertise being strategic interactions between stakeholders in supply chains, including looking at socially responsible operations. As such, she is well-placed to explore this area of study.
The Global Centre for Healthcare Convergence (GCHC) will optimise health outcomes for specific populations at risk escalation point by introducing Precision Population Health Solutions™. This scalable, evidence-based business model will bring an end to harmful health system fragmentation for these populations, by aligning interests of digital, pharmaceutical, diagnostic, data technologies with payments, health provider workforce, local incentives and government stakeholders to achieve better patient outcomes.
Based in Cambridge Judge Business School, part of the rich academic lineage of the University, we engage in research and teaching activities aiming to improve both academic knowledge and the practice of management in health-related organisations and industries.
Our goal is better health for more people. We draw on business school faculty across management disciplines, from organisational behaviour and operations management to marketing and strategy, as well as from partners with the relevant industry expertise.
Clinical leadership is about driving change from the front line, rather than waiting until it is imposed from back offices by managers or regulators.
News and insights from the Cambridge Centre for Health Leadership & Enterprise
Read the latest news and insights from Cambridge Centre for Health Leadership & Enterprise.
When COVID-19 travel restrictions were introduced, it sparked a trend towards remote participation in clinical assessments of new medicines’ safety and efficacy. A new study co-authored at Cambridge Judge Business School outlines a framework to assess when decentralised drug trials provide the greatest value to the system.
Increased drug supply security and reduced costs has been achieved by Civica Rx, a health care utility taking a fresh approach, says study in NEJM Catalyst authored by 2 Cambridge Judge Business School academics.
Stefan Scholtes of Cambridge Judge Business School wins Collaboration Award in the Vice Chancellor’s Awards for Research Impact and Engagement for work on the COVID pandemic. Khal Soufani of Cambridge Judge is runner-up in Established Academic award for work in circular economy.